Considerations for characterizing the risk of PML in natalizumab-treated patients

Mult Scler Relat Disord. 2016 Sep:9:121. doi: 10.1016/j.msard.2016.07.008. Epub 2016 Jul 11.
No abstract available

Publication types

  • Letter

MeSH terms

  • Algorithms*
  • Antibodies, Viral / blood
  • Clinical Studies as Topic
  • Humans
  • Immunologic Factors / adverse effects*
  • Immunologic Factors / therapeutic use
  • JC Virus / immunology
  • Leukoencephalopathy, Progressive Multifocal / diagnosis
  • Leukoencephalopathy, Progressive Multifocal / epidemiology
  • Leukoencephalopathy, Progressive Multifocal / etiology*
  • Leukoencephalopathy, Progressive Multifocal / immunology
  • Natalizumab / adverse effects*
  • Natalizumab / therapeutic use
  • Risk Assessment

Substances

  • Antibodies, Viral
  • Immunologic Factors
  • Natalizumab